Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson’s Disease Model

Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson’s Disease Model

The α-synuclein aggregates are the main component of Lewy bodies in Parkinson’s disease (PD) brain, and they showed immunotherapy could be employed to alleviate α-synuclein aggregate pathology in PD. Recently we have generated DNA aptamers that specifically recognize α-synuclein. In this study, we f...

Full description

Bibliographic Details
Main Authors:	Xiaoxi Ren, Yun Zhao, Fenqin Xue, Yan Zheng, Haixia Huang, Wei Wang, Yongchang Chang, Hui Yang, Jianliang Zhang
Format:	Article
Language:	English
Published:	Elsevier 2019-09-01
Series:	Molecular Therapy: Nucleic Acids
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253119301982

Similar Items

Novel DNA Aptamers for Parkinson’s Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation
by: Yuan Zheng, et al.
Published: (2018-06-01)

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson’s disease
by: Xiao-yun Niu, et al.
Published: (2024-04-01)

Exosome release and neuropathology induced by α-synuclein: new insights into protective mechanisms of Drp1 inhibition
by: Rebecca Z. Fan, et al.
Published: (2019-11-01)

Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
by: Laura Boi, et al.
Published: (2020-11-01)

Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease
by: Ya-ru Huang, et al.
Published: (2019-04-01)

MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson’s disease
by: Lu Geng, et al.
Published: (2023-12-01)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
by: Derya Emin, et al.
Published: (2022-09-01)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
by: Xin Yuan, et al.
Published: (2022-01-01)

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease
by: Eva Nordström, et al.
Published: (2021-12-01)

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
by: David J. Rademacher
Published: (2023-04-01)

Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms
by: Mario Meloni, et al.
Published: (2023-01-01)

Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson’s disease
by: Jeong-Yong Shin, et al.
Published: (2022-12-01)

Monitoring α-synuclein aggregation
by: Juan Estaun-Panzano, et al.
Published: (2023-01-01)

Heparin induces α-synuclein to form new fibril polymorphs with attenuated neuropathology
by: Youqi Tao, et al.
Published: (2022-07-01)

Kinetics of α-synuclein prions preceding neuropathological inclusions in multiple system atrophy.
by: Amanda L Woerman, et al.
Published: (2020-02-01)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
by: Bojie Yang, et al.
Published: (2023-04-01)

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
by: Kenji Yamamoto, et al.
Published: (2013-03-01)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
by: Hayate Javed, et al.
Published: (2019-03-01)

Spreading of Aggregated α-Synuclein in Sagittal Organotypic Mouse Brain Slices
by: Buket Uçar, et al.
Published: (2022-01-01)

Alpha-Synuclein Aggregation in Parkinson's Disease
by: E. Srinivasan, et al.
Published: (2021-10-01)

The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity
by: Jing Qu, et al.
Published: (2018-07-01)

Recent advances in natural products targeting α-synuclein aggregation or clearance in Parkinson's disease
by: Jay Gupta, et al.
Published: (2023-12-01)

Optogenetic-mediated induction and monitoring of α-synuclein aggregation in cellular models of Parkinson’s disease
by: Maxime Teixeira, et al.
Published: (2023-12-01)

Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease
by: Gabriela Henriquez, et al.
Published: (2023-08-01)

Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein
by: Takashi Ohgita, et al.
Published: (2022-04-01)

Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease
by: Matilde Bongianni, et al.
Published: (2022-07-01)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
by: Ariadna Recasens, et al.
Published: (2018-02-01)

Decreasing α-synuclein aggregation by methanolic extract of Centella asiatica in zebrafish Parkinson's model
by: Husnul Khotimah, et al.
Published: (2015-11-01)

Inflammatory Responses to Monomeric and Aggregated α-Synuclein in Peripheral Blood of Parkinson Disease Patients
by: Federica Piancone, et al.
Published: (2021-03-01)

New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.
by: Sonia Lehri-Boufala, et al.
Published: (2015-01-01)

Increased DJ-1 and α-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson’s Disease
by: Zhen-Hua Zhao, et al.
Published: (2019-01-01)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
by: Dimitrios Anagnostou, et al.
Published: (2023-06-01)

Inhibition of α-Synuclein Aggregation by the Interaction Between Protein Disulfide Isomerase and α-Synuclein
by: PEI Yun-shan1,2, ZHANG Cai1,2, LIU Xiao-li1, CHENG Kai1, ZHANG Ze-ting,1, LI Cong-gang1
Published: (2022-12-01)

Inducing α-synuclein compaction: a new strategy for inhibiting α-synuclein aggregation?
by: Francisca Pinheiro, et al.
Published: (2019-01-01)

Impaired aldehyde detoxification exacerbates motor deficits in an alpha‐synuclein mouse model of Parkinson's disease
by: Paul Anthony Martinez, et al.
Published: (2023-09-01)

Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys
by: Diana Alarcón-Arís, et al.
Published: (2020-09-01)

Running wheel exercise reduces α-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson's disease.
by: Wenbo Zhou, et al.
Published: (2017-01-01)

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
by: Sara Hall, et al.
Published: (2022-06-01)

α-Synuclein Oligomer Detection with Aptamer Switch on Reduced Graphene Oxide Electrode
by: Seung Joo Jang, et al.
Published: (2020-04-01)

Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease
by: Matilde Bongianni, et al.
Published: (2022-08-01)